针对气道上皮的纳米粒子在吸入治疗中逆转了喘
Yinglan Yu1, Mingjie Ni2, Yaxian Zheng3
1College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
概括
这项研究开发了针对性纳米颗粒用于喘治疗. 这些纳米粒子增强药物输送到肺部,改善治疗效果并减少喘模型中的炎症.
科学领域:
- 纳米医学是一种纳米医学.
- 肺部药物输送 肺部药物输送
- 免疫学 免疫学 免疫学
背景情况:
- 皮质类固醇对于喘治疗至关重要,但其肺部停留时间有限.
- 纳米颗粒有可能延长肺部药物保留时间,但粘液和气道清除阻碍了它们的有效性.
- 现有的纳米粒子策略面临着粘液透和气道中细胞相互作用的挑战.
研究的目的:
- 开发功能化纳米颗粒,克服气道障碍,以增强肺部药物输送.
- 调查新生儿Fc受体向 (FcBP) 修饰对纳米粒子粘液透性和细胞相互作用的影响.
- 在喘小鼠模型中评估FcBP修饰的甲装载纳米颗粒的治疗疗效.
主要方法:
- 聚乙烯糖醇 (PEG) 纳米颗粒的功能化与FcBP.
- 评估粘液透性和细胞吸收/转运的改性纳米颗粒.
- 用德甲加载纳米颗粒并评估它们的 in vitro 和 in vivo 效果.
- 在喘小鼠模型中进行体内测试,以评估治疗结果和肺保留.
主要成果:
- FcBP功能化并没有阻碍PEG纳米颗粒的粘液透能力.
- 通过受体介导的过程,FcBP修饰增强了细胞内部化和体运输.
- 装载着甲的FcBP纳米颗粒有效地穿过呼吸道上皮,并被炎症细胞内化.
- FcBP-纳米颗粒显著降低了炎症性细胞因子,并改善了喘小鼠的治疗结果,延长了肺保留时间.
结论:
- 具有FcBP功能的PEG纳米粒子克服了气道障碍,增强了肺部药物保留和输送.
- 这一策略为改善喘等呼吸道疾病的吸入疗法提供了一个有希望的方法.
- 修改FcBP代表了一种改进纳米粒子药物输送到肺部的新方法.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
300
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
300
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298
01:17Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
01:20Asthma: Pathogenesis and Management
403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
251
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
251